17.77
+0.68(+3.98%)
Currency In USD
Address
3957 Point Eden Way
Miami, CA 94545
United States of America
Phone
510 906 4600
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
75
First IPO Date
May 18, 2016
| Name | Title | Pay | Year Born |
| Mr. Paul Arthur LaViolette | President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer & Co-Chairman of the Board | 52,916 | 1958 |
| Mr. Robert W. Duggan | Independent Co-Chairman | 9,126 | 1945 |
| Mr. Mitchell E. Levinson | Chief Strategy Officer | 584,565 | 1960 |
| Mr. Darrin R. Uecker | Chief Technology Officer & Director | 616,410 | 1966 |
| Mr. Kevin P. Danahy | Chief Commercial Officer & Principal Executive Officer | 616,410 | 1971 |
| Mr. Jon Skinner | Chief Financial Officer | 0 | 1986 |
| Dr. Richard Nuccitelli Ph.D. | Chief Science Officer | 0 | N/A |
| Mr. Edison Manuel | Vice President of Operations | 0 | N/A |
| Mr. Kenneth B. Stratton Esq., J.D. | General Counsel & Corporate Secretary | 0 | 1969 |
| Ms. Patty Perla | Vice President of Human Resources | 0 | N/A |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.